The European Medicines Agency selected TrialAssure’s ANONYMIZE platform as an official anonymization tool for market authorization holders to redact public clinical trial documents. EMA said the deployment supports Policy 0043 requirements, which mandate public posting of clinical documents while protecting participant identity and privacy. TrialAssure’s approach combines AI-assisted detection with expert review to handle sensitive data across dossiers and images. The selection follows structured vendor evaluation and is framed as a scalable solution for consistent compliance across the EU and EEA. For sponsors, the change could reduce iteration cycles for redaction workflows and improve predictability for how dossiers will be reviewed before public release.